SECENDS - WMT

2025

Q4 3 filings

Nov

Q3 Earnings + NYSE to Nasdaq Transfer

Q3 2025 results disclosed, stock/debt moving NYSE to Nasdaq Dec 9

8-K

Nov

CEO Transition

McMillon retiring Jan 31, 2026; Furner appointed new CEO

8-K

Oct

Controller Appointed

Dwayne Milum appointed SVP & Controller, $600K salary

8-K

Q3 5 filings

Sep

Executive 10b5-1 Trading Plan

Chief People Officer plans to sell max 148,665 shares starting Jan 2026

8-K

Sep

Executive 10b5-1 Trading Plan

Daniel Danker to sell max 109,976 shares via automated plan

8-K

Sep

CFO 10b5-1 Trading Plan

CFO Rainey to sell 40,000 shares in Feb-Mar 2026

8-K

Aug

Q2 2025 Results

Rev $177.4B (+4.8% YoY), EPS $0.88 (+57% YoY)

10-Q

Aug

Q2 Earnings

Results for three and six months ended July 31, 2025

8-K

Q2 6 filings

Jun

Annual Shareholder Meeting

91.36% turnout, all 12 directors elected, 7 shareholder proposals rejected

8-K

Jun

Q1 2025 Results

Rev $165.6B (+2.5% YoY), EPS $0.56 (-11.1% YoY)

10-Q

May

Q1 Earnings + HQ Relocation

Q1 2025 results for quarter ended April 30, HQ moved to 1 Customer Drive

8-K

Apr

Debt Offering

$4B notes issued: Floating rate 2027, 4.1% 2027, 4.35% 2030, 4.9% 2035

8-K

Apr

2025 Proxy Statement

CEO comp: 82% performance-based, Dividend: +13% to $0.94/share

DEF 14A

Apr

Investment Community Meetings

Press release issued for investor meetings

8-K

Q1 4 filings

Mar

John Furner 10b5-1 Trading Plan

157,500 shares max sale over 12 months

8-K

Mar

CEO 10b5-1 Trading Plan

McMillon to sell 233,000 shares Jun 2025-May 2026

8-K

Mar

FY2025 2025 Results

Unable to extract specific revenue and EPS figures from provided XBRL data format

📌 Filing date of March 14, 2025 for fiscal year ending January 31, 2025

10-K

Feb

Q4 FY2025 Earnings

Results for Q4 and fiscal year ended January 31, 2025

8-K

2024

Q4 4 filings

Dec

Q3 2024 Results

Financial data not available in provided content

10-Q

Nov

Executive 10b5-1 Trading Plan

Kathryn McLay to sell 40,000 shares over 10 months

8-K

Nov

Q3 Earnings

Results for three and nine months ended October 31, 2024

8-K

Oct

Opioid Derivative Lawsuit Settlement

$123M insurance payout to settle opioid-related shareholder derivative claims

8-K

Q3 4 filings

Sep

CFO 10b5-1 Trading Plan

CFO Rainey to sell max 95,800 shares through Dec 2025

8-K

Aug

Q2 2024 Results

Rev $169.3B (+4.8% YoY), EPS $0.56 (-42.9% YoY)

10-Q

Aug

Director Appointed

Robert E. Moritz Jr. appointed to Board

8-K

Aug

Q2 2024 Earnings

Results for three and six months ended July 31, 2024

8-K

Q2 4 filings

Jun

Q1 2024 Results

Rev $161.5B (+6.0% YoY), EPS $0.63 (+200% YoY)

10-Q

Jun

Annual Shareholder Meeting

91% attendance, all 11 directors elected, executive comp approved

8-K

May

Q1 2024 Earnings

Results for three months ended April 30, 2024

8-K

Apr

2024 Proxy Statement

CEO comp: >80% performance-based, Stock split: 3-for-1

DEF 14A